Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with copd in the TONADO® and OTEMTO® studies: A subgroup analysis by age

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 2701-2710

  Ferguson, Gary T ^a   Karpel, Jill P ^b   Clerisme Beaty, Emmanuelle ^c   Grönke, Lars ^d   Voß, Florian ^d   Buhl, Roland ^e  

^a Pulmonary Research Institute of Southeast Michigan   (United States)

^b North Shore Medical Arts LLP   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

FEV1; Lung function; Rescue medication; SGRQ; TDI

Indexed keywords

OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DRUG COMBINATION; TIOTROPIUM BROMIDE; TIOTROPIUM-OLODATEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING; VERY ELDERLY; AGE; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECTS; LUNG; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BENZOXAZINES; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COMBINATIONS; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LUNG; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 85016080342     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S108758     Document Type: Article

References (34)

1. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2016. Available from: http://www.goldcopd.org/. Accessed April 27, 2016.
2. Feenstra TL, van Genugten MLL, Hoogenveen RT, Wouters EF, Rutten-van Mölken MPH. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164(4):590–596.
3. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185.
4. Roberts MH, Mapel DW, Thomson HN. The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease. Clinicoecon Outcomes Res. 2015;7:173–184.
5. Anecchino C, Rossi E, Fanizza C, et al. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis. 2007;2(4):567–574.
6. Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011;37(3):508–515.
7. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–224.
8. O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840.
9. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168–1178.
10. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
11. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med. 2010; 104(10):1460–1472.
12. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care. 2011;56(4):477–487.
13. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103.
14. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–645.
15. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714.
16. 1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. Spring-erplus. 2014;3:419.
17. Lange P, Aumann J-L, Hamilton A, Tetzlaff K, Ting N, Derom E. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med. 2014;4:196.
18. Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015;8(5):529–539.
19. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319.
20. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixeddose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979.
21. Jones PW. Estimation and application of the minimum clinically important difference in COPD. Lancet Respir Med. 2014;2(3):167–169.
22. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003; 21(2):267–272.
23. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Eur Respir J. 1993; 6(suppl 16):5–40.
24. Pride NB. Ageing and changes in lung mechanics. Eur Respir J. 2005; 26(4):563–565.
25. Satoh H, Kagohashi K, Ohara G, et al. Use of tiotropium in patients with COPD aged 80 years and older. Exp Ther Med. 2013;5(4):997–1000.
26. Schirnhofer L, Lamprecht B, Vollmer WM, et al. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest. 2007;131(1):29–36.
27. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969.
28. Lahousse L, Ziere G, Verlinden VJA, et al. Risk of frailty in elderly with COPD: a population-based study. J Gerontol A Biol Sci Med Sci. 2016;71(5):689–695.
29. Scanlon PD, Connett JE, Wise RA, et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med. 2004;170(12):1302–1309.
30. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med. 2009;103(2):224–229.
31. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009;58(6):417–424.
32. Santus P, Radovanovic D, Di Marco S, et al. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015;10:1917–1923.
33. National Institute for Health and Care Excellence [webpage on the Internet]. Chronic Obstructive Pulmonary Disease in over 16s: Diagnosis and Management. Clinical Guideline. NICE Guidelines [CG101]; 2010. Available from: http://www.nice.org.uk/guidance/cg101/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-35109323931589. Accessed November 18, 2015.
34. American Medical Directors Association (AMDA). COPD Management in the Long-Term Care Setting. Columbia: AMDA; 2010.